The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...
Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced the successful completion of the Phase III clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results